Table of Contents
- Clinical trials overview
- Conditions being studied
- Who can take part
- Trial phases and study designs
- Main endpoints and what they mean
- Selected trial examples
- What these studies mean for patients
Clinical trials overview
The source data includes many interventional studies of Human Normal Immunoglobulin, with trials in Phase 2, Phase 3, Phase 4, and low-intervention settings.[1] These studies are testing the treatment in different groups of patients, including people with immune deficiency, infection risk, nerve disease, muscle disease, and some blood cancers.[1]
Several trials compare Human Normal Immunoglobulin with placebo or standard care, while others compare one immunoglobulin product with another product or study how well a product works over time.[1] The goals include checking efficacy, safety, tolerability, and in some studies, pharmacokinetics, which means how the treatment moves through the body.[1]
Conditions being studied
The trials cover a wide range of conditions, showing that Human Normal Immunoglobulin is being studied in both immune and non-immune diseases.[1] Important groups include primary immunodeficiency diseases, primary antibody deficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), dermatomyositis, idiopathic inflammatory myopathy, and primary Sjögren’s syndrome-related neuropathies.[1]
Other studies focus on infection prevention in people with multiple myeloma, chronic lymphocytic leukemia, non-Hodgkin lymphoma, kidney transplant recipients, and patients receiving B-cell depletion therapy.[1] There are also trials in post-COVID-19 POTS, COVID-19 with severely impaired B-cell function, pediatric acute-onset neuropsychiatric syndrome, Kawasaki disease, and non-cystic fibrosis bronchiectasis.[1]
Who can take part
Each trial has its own entry rules, called eligibility criteria, and these depend on the disease being studied.[1] Some studies are for adults only, such as trials in multiple myeloma, CIDP, post-COVID-19 POTS, and idiopathic inflammatory myopathy, while others include children, such as the trial in pediatric acute-onset neuropsychiatric syndrome.[1]
Some studies focus on people with low antibody levels or weak immune function, such as hypogammaglobulinemia, primary immunodeficiency, or severe B-cell problems.[1] Other studies enroll people with a specific diagnosis and a certain treatment history, such as patients who failed initial IVIG treatment in Kawasaki disease or those with relapsed or refractory multiple myeloma.[1]
Trial phases and study designs
Most of the listed studies are Phase 3, which usually means a larger trial that compares treatments and confirms benefit and safety.[1] The source data also includes Phase 2 trials, which often look for early signs of benefit, and Phase 4 trials, which study treatment use after wider clinical use has begun.[1]
Some studies are open-label, which means everyone knows which treatment is given, and some are double-blind, which means neither the patient nor the doctor knows the treatment assignment.[1] Several are randomized, meaning participants are assigned by chance to different treatment groups to make the comparison fair.[1]
Main endpoints and what they mean
The primary endpoint is the main result the study is designed to measure.[1] In these trials, common primary endpoints include serious bacterial infections, major infections, time to first infection, relapse events, disability scores, pain scores, response rates, and progression-free survival (PFS), which means the time before the disease gets worse.[1]
Some studies measure disease-specific scores such as mRS, ODSS, CY-BOCS, MG-ADL, QMG, and total improvement score (TIS).[1] Others measure lab or body-based outcomes, such as total IgG levels, area under the curve (AUC), or the number of treatment-emergent adverse events, which are health problems that start after treatment begins.[1]
Selected trial examples
NCT04640142 studied subcutaneous human immunoglobulin in people with primary immunodeficiency diseases and measured the rate of serious bacterial infections per person-year, plus average IgG levels at steady state.[1] This was a Phase 3 study with 72 participants and was completed.[1]
NCT07048262 is a Phase 2 study in adults with non-cystic fibrosis bronchiectasis, testing nebulized Human Normal Immunoglobulin for time to first exacerbation, which means how long it takes before symptoms worsen again.[1] The study is authorised and plans to enroll 459 people.[1]
NCT04222023 is a low-intervention multicenter study in kidney transplant recipients, looking at whether preventive IVIG lowers the incidence of BKV viremia, which means virus in the blood, after transplantation.[1] It plans to include 664 participants and is authorised.[1]
NCT04502030 tested Panzyga in people with chronic lymphocytic leukemia and secondary hypogammaglobulinemia to prevent infections, with the main endpoint being whether at least one major infection occurs.[1] This was a Phase 3, placebo-controlled study with 240 participants and was completed.[1]
NCT04508530 studied Panzyga in pediatric acute-onset neuropsychiatric syndrome and measured change in CY-BOCS score, a clinician-rated symptom scale.[1] It was a completed Phase 3 study with 92 children and adolescents.[1]
What these studies mean for patients
These trials show that Human Normal Immunoglobulin is being tested for both prevention and treatment goals, depending on the disease.[1] For some patients, the main aim is to lower infection risk; for others, it is to improve nerve, muscle, or brain-related symptoms, or to reduce relapse and disability.[1]
Because the trials use different designs and outcome measures, the results will not be the same for every condition.[1] Together, they help researchers learn where Human Normal Immunoglobulin may be useful, how well it works, and how safe it is in the studied groups.[1]
